ZORYVE's Q1: Soaring Revenues, Expanding Pipeline

Arcutis Biotherapeutics, the company behind ZORYVE, reported a significant increase in net product revenues for Q1, with a 65% year-over-year growth despite seasonal dips. Theyre focusing on expanding their core business in approved skin conditions and have ramped up their sales team. Positive trial data for ZORYVE in infants has led to a supplemental NDA filing for atopic dermatitis in babies. The company is also making progress on their pipeline, with phase two trials nearing completion and new biologics in development. Their cash flow positive status and guidance for full-year revenues set them up for future growth. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/3b71aa65cbf974f0